An online decision tool created in part by a graduate student at the University of California Irvine helps men diagnosed with prostate cancer sort through an intimidating flurry of possible treatments and customize treatment plans of their own, according to a study in the current issue of Interfaces, a journal of the Institute for Operations Research and the Management Sciences (INFORMS®).
Body
TORONTO—Combining high-definition positron emission tomography (PET) and "motion-frozen" technology provides enhanced cardiac images. The motion-frozen technology adds physiological details that were previously invisible to physicians, according to researchers at SNM's 56th Annual Meeting in Toronto. A new study of the combined technologies shows that the method provides exceptional PET image quality and can significantly change the diagnosis of patients with heart disease.
TORONTO—A major barrier to developing a hybrid positron emission tomography (PET)/magnetic resonance (MR) imaging system could be removed by using a novel approach for reconstructing data, according to researchers at SNM's 56th Annual Meeting in Toronto. Many researchers view fused PET/MR as an important next step in improving imaging capabilities and believe that PET/MR could become a viable alternative to hybrid PET/computed tomography (CT) systems.
TORONTO—A new study reveals that PET scans accurately detect infections in prosthetic knee joints more than 90 percent of the time, according to researchers at the SNM's 56th Annual Meeting. The findings could represent a significant breakthrough in the treatment of patients who undergo joint replacements. Joint replacements are prone to a number of complications following implantation.
LEXINGTON, Ky. (June 15, 2009) – A team of researchers led by Dr. Jayakrishna Ambati at the University of Kentucky has discovered a biological marker for neovascular age-related macular degeneration (AMD), the leading cause of blindness in older adults.
The marker, a receptor known as CCR3, shows strong potential as a means for both the early detection of the disease and for preventive treatment. The findings were reported in an article published online Sunday by the prestigious journal Nature.
With the H1N1 flu outbreak now elevated to pandemic level, a new article http://www.cmaj.ca/cgi/rapidpdf/cmaj.090866 in CMAJ (Canadian Medical Association Journal) reports that oseltamivir (Tamiflu®) and zanamivir (Relenza®) are relatively safe drugs for use in pregnant and breast-feeding women.
Pregnant women, especially those in the third trimester, are at high risk of serious complications from the H1N1 A influenza virus.
Westchester, Ill. –A study in the June 15 issue of the Journal of Clinical Sleep Medicine shows that the complaints of fatigue and tiredness in patients with obstructive sleep apnea (OSA) improved significantly with good adherence to continuous positive airway pressure (CPAP) therapy, suggesting that - like the symptom of excessive daytime sleepiness - these complaints are important symptoms of OSA.
One of the mechanisms governing how our physical features and behavioural traits have evolved over centuries has been discovered by researchers at the University of Leeds.
Darwin proposed that such traits are passed from a parent to their offspring, with natural selection favouring those that give the greatest advantage for survival, but did not have a scientific explanation for this process.
Scientists from the Helmholtz Center for Infection Research in Braunschweig, Germany and the Medical School Hannover, Germany have succeeded in treating immune cells in a way that enables them to inhibit unwanted immune reactions such as organ rejection. Their results have now been published in the current issue of the scientific journal Journal of Cellular and Molecular Medicine.
Amsterdam, 15 June 2009 - Elsevier announced today the publication of the May 2009 issue of Reproductive Health Matters, on the theme of task shifting. The issue describes innovative efforts to increase access to skilled reproductive health care, particularly in resource-poor settings.
Scientists from A*STAR's Singapore Immunology Network (SIgN) and the University of Milano-Bicocca, Italy, have discovered another signaling pathway for the activation and apoptosis, or programmed cell death, of dendritic cells[1] . This discovery was published in the advanced online publication of Nature on 15 Jun 2009.
Scientists from A*STAR's Institute of Materials Research andEngineering (IMRE), led by Professor Christian Joachim, have scored abreakthrough in nanotechnology by becoming the first in the world to invent amolecular gear of the size of 1.2nm whose rotation can be deliberatelycontrolled. This achievement marks a radical shift in the scientific progress ofmolecular machines and is published on 15 June 20092 in Nature Materials(*).
Jerusalem, June 14, 2009 – Research by a Hebrew University of Jerusalem professor has led to the development of a product that has been shown in clinical trials to be successful in halting the growth of various types of cancer cells.
The research, conducted by Prof. Avraham Hochberg of the Silberman Institute of Life Sciences at the university, has won for him first prize among faculty members for this year's Kaye Innovations Awards, which was presented on June 9 during the annual Hebrew University Board of Governors meeting.
St. Louis, MO, June 15, 2009 – Calcium and dairy products play major roles in health maintenance and the prevention of chronic disease. Because peak bone mass is not achieved until the third decade of life, it is particularly important for young adults to consume adequate amounts of calcium, protein and vitamin D found in dairy products to support health and prevent osteoporosis later in life.
A new prostate cancer risk assessment test, developed by a UCSF team, gives patients and their doctors a better way of gauging long-term risks and pinpointing high risk cases.
According to UCSF study findings, published this week, the test proved accurate in predicting bone metastasis, prostate cancer-specific mortality, and all-cause mortality when localized prostate cancer is first diagnosed. The test is known as the UCSF Cancer of the Prostate Risk Assessment, or CAPRA.